Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 3/20 | 0.37 |
| ▸ | USP14 | P54578 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | IDO1 | P14902 | 2/20 | 0.36 |
| ▸ | AGXT | P21549 | 2/20 | 0.36 |
| ▸ | CNR1 | P21554 | 11/20 | 0.35 |
| ▸ | CNR2 | P34972 | 9/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6800371 | 0.89 | AGXT (0.35) | IDO1AGXTMAPT | |
| SCHEMBL21367138 | 0.80 | CYP3A4 (0.56) | CYP3A4IDO1AGXTMAPT | |
| SCHEMBL17030654 | 0.76 | IDO1 (0.50) | USP14IDO1AGXTMAPT | |
| SCHEMBL6031606 | 0.76 | TAAR1 (0.41) | CYP3A4IDO1AGXT | |
| SCHEMBL15687564 | 0.74 | IDO1 (0.36) | USP14CYP3A4IDO1AGXT | |
| SCHEMBL840465 | 0.72 | GABRA1 (0.45) | CYP3A4MAPT | |
| SCHEMBL11942311 | 0.72 | IDO1 (0.38) | CYP3A4IDO1AGXT | |
| SCHEMBL722684 | 0.71 | IDO1 (0.56) | IDO1AGXT | |
| SCHEMBL501378 | 0.71 | MRGPRX4 (0.41) | USP14IDO1 | |
| SCHEMBL631424 | 0.71 | MAOB (0.42) | CYP19A1CYP3A4IDO1AGXT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040235816-A1 | Azetidine derivatives, their preparation and medicaments containing them | AVENTIS PHARMA S.A. (FR) | 2004-11-25 | — | — | US | disclosed |
| US-20020035102-A1 | Azetidine derivatives, their preparation and medicaments containing them | AVENTIS PHARMA S.A. (FR) | 2002-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235816-A1 | Azetidine derivatives, their preparation and medicaments containing them | AZI2, ADRA2A, ADRA2C | CYP19A1 467/4885USP14 736/4885CYP3A4 68/4885 |
| US-20020035102-A1 | Azetidine derivatives, their preparation and medicaments containing them | CYP11B2, AZI2, CYP2C19 | CYP19A1 123/4885USP14 1708/4885CYP3A4 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.